Agios Pharmaceuticals Inc. (Nasdaq: AGIO) reported initial data from a Phase 1 clinical trial of AG-519. Shares of the biopharmaceutical plummeted $9.87 to close at $56.22.
Agios Pharmaceuticals reports initial data
June 09, 2016 at 17:07 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.